ABSTRACT:

Portal hypertension and liver failure can arise as a result of liver cirrhosis, a chronic illness characterized by the fibrosis and renewal of nodules in the liver. A number of long-term conditions can lead to cirrhosis, a progressive disease. after a few years or perhaps decades. Liver cirrhosis is one public health concern. Metabolic syndrome, autoimmune diseases, storage diseases, drug use, alcohol consumption, viral hepatitis, and toxic chemicals are the usual causes. Cirrhosis is the fourteenth most prevalent cause of death in adults. placing ninth overall and fourth in Europe and the US. Because this condition is symptomatic and often remains undiagnosed in its early stages, its frequency is underestimated. It typically progresses to the decompensated stage at a rate of 5 to 7% annually. Here, we discuss the pathophysiology, epidemiology, diagnosis, and etiology of liver cirrhosis.

KEYWORDS:

Liver cirrhosis; epidemiology; etiology; risk factors; pathophysiology.

REFERENCES :

1) Zhou, W.C.; Zhang, Q.B.; Qiao, L. Pathogenesis of liver cirrhosis. World journal of gastroenterology 2014 , 20, 7312-7324, doi:10.3748/wjg.v20.i23.7312.
2) Wiegand, J.; Berg, T. The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis. Deutsches Arzteblatt international 2013, 110, 85-91, doi:10.3238/arztebl.2013.0085
3) Asrani, S.K.; Devarbhavi, H.; Eaton, J.; Kamath, P.S. Burden of liver diseases in the world. Journal of hepatology 2019, 70, 151-171, doi:10.1016/j.jhep.2018.09.014.
4) Marcellin, P.; Kutala, B.K. Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. Liver international : official journal of the International Association for the Study of the Liver 2018, 38 Suppl 1, 2-6, doi:10.1111/liv.13682.
5) Rowe, I.A. Lessons from Epidemiology: The Burden of Liver Disease. Digestive diseases 2017, 35, 304 – 309 , doi:10.1159/000456580.
6) Poordad, F.F. Presentation and complications associated with cirrhosis of the liver. Current medical research and opinion 2015, 31, 925-937, doi:10.1185/03007995.2015.1021905.
7) Pimpin, L.; Cortez-Pinto, H.; Negro, F.; Corbould, E.; Lazarus, J.V.; Webber, L.; Sheron, N .; Committee, E.H.S. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. Journal of hepatology 2018, 69, 718-735, doi:10.1016/j.jhep.2018.05.011
8) Collaboration, G.B.o.D.L.C. The Burden of Primary Liver Cancer and Underlying Etiologies From to 2015 at the Global, Regional, and National Level: Results From the Global Burden1990 of Disease Study 2015The Global Burden of Liver Cancer 2015The Global Burden of Liver Cancer 2015. JAMA Oncology 2017, 3, 1683-1691, doi:10.1001/jamaoncol.2017.3055 .
9) Rawla, P.; Sunkara, T.; Muralidharan, P.; Raj, J.P. Update in global trends and aetiology of hepatocellular carcinoma. Contemporary oncology 2018, 22, 141-150, doi:10.5114/wo.2018.78941
10) Wong, M.C.S.; Huang, J. The growing burden of liver cirrhosis: implications for preventive measures . Hepatology international 2018, 12, 201-203, doi:10.1007/s12072-018-9865-y .
11) Stasi, C.; Silvestri, C.; Voller, F.; Cipriani, F. Epidemiology of Liver Cirrhosis. Journal of clinical and experimental hepatology 2015, 5, 272, doi:10.1016/j.jceh.2015.06.002 .
12) Schuppan, D.; Afdhal, N.H. Liver cirrhosis. Lancet (London, England) 2008, 371, 838-851 , doi:10.1016/S0140-6736(08)60383-9 .
13) Sivanathan, V.; Kittner, J.M.; Sprinzl, M.F.; Weinmann, A.; Koch, S.; Wiltink, J.; Nguyen-Tat, M .; Marquardt, J.U.; Worns, M.A.; Zimmermann, T., et al. [Etiology and complications of liver cirrhosis : data from a German centre]. Deutsche medizinische Wochenschrift (1946) 2014, 139, 1758-1762 , doi:10.1055/s-0034-1387240 .
14) Nusrat, S.; Khan, M.S.; Fazili, J.; Madhoun, M.F. Cirrhosis and its complications: evidence based treatment. World journal of gastroenterology 2014, 20, 5442-5460, doi:10.3748/wjg.v20.i18.5442
15) Rahimi, R.S.; Rockey, D.C. Complications of cirrhosis. Current opinion in gastroenterology 2012, 28, 223 – 229 , doi:10.1097/MOG.0b013e328351d003.
16) Wittenburg, H.; Tennert, U.; Berg, T. [Complications of liver cirrhosis]. Der Internist 2011, 52, 1061 – 10707.
17) Suk, K.T.; Kim, D.J. Staging of liver fibrosis or cirrhosis: The role of hepatic venous pressure gradient measurement. World journal of hepatology 2015, 7, 607-615, doi:10.4254/wjh.v7.i3.607
18) Tsochatzis, E.A.; Bosch, J.; Burroughs, A.K. Liver cirrhosis. Lancet 2014, 383, 1749-1761 , doi:10.1016/s0140-6736(14)60121-5
19) Piano, S.; Singh, V.; Caraceni, P.; Maiwall, R.; Alessandria, C.; Fernandez, J.; Soares, E.C.; Kim, D.J .; Kim, S.E.; Marino, M. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide. Gastroenterology 2018.
20) Mohammed, S.E.A.; Abdo, A.E.; Mudawi, H.M.Y. Mortality and rebleeding following variceal haemorrhage in liver cirrhosis and periportal fibrosis. World journal of hepatology 2016, 8, 1336-1342 , doi:10.4254/wjh.v8.i31.1336 .
21) Romcea, A.; Tanţău, M.; Seicean, A.; Pascu, O. Variceal bleeding in cirrhotic patients: risk factors , evolution, treatment. Clujul medical (1957) 2013, 86, 107-110 .
22) Bajaj, J.S.; O’Leary, J.G.; Tandon, P.; Wong, F.; Garcia-Tsao, G.; Kamath, P.S.; Maliakkal, B.; Biggins , S.W.; Thuluvath, P.J.; Fallon, M.B., et al. Hepatic Encephalopathy Is Associated With Mortality in Patients With Cirrhosis Independent of Other Extrahepatic Organ Failures. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2017, 15 , 565-574.e564, doi:10.1016/j.cgh.2016.09.157.
23) Rawla, P.; Thandra, K.C.; Vellipuram, A.; Ali, C.D.M. Efficacy and safety of megestrol in the management of hepatocellular carcinoma: a systematic review of the literature. Contemporary oncology 2018 , 22, 209-214, doi:10.5114/wo.2018.82641.
24) Bustamante, J.; Rimola, A.; Ventura, P.J.; Navasa, M.; Cirera, I.; Reggiardo, V.; Rodes, J. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. Journal of hepatology 1999, 30, 890
25) Suraweera, D.; Konyn, P.; Vu, T.; Saab, S. Clinical Epidemiology of Chronic Liver Disease : Hepatocellular Carcinoma. In Clinical Epidemiology of Chronic Liver Diseases, Springer: 2019; pp. 229
26) Petrick, J.L.; Kelly, S.P.; Altekruse, S.F.; McGlynn, K.A.; Rosenberg, P.S. Future of hepatocellular carcinoma incidence in the United States forecast through 2030. Journal of Clinical Oncology 2016, 34
27) White, D.L.; Thrift, A.P.; Kanwal, F.; Davila, J.; El-Serag, H.B. Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. Gastroenterology 2017, 152, 812-820. e815
28) Byass, P. The global burden of liver disease: a challenge for methods and for public health. BMC medicine 2014, 12, 159-159, doi:10.1186/s12916-014-0159-5 .
29) Angeli, P.; Ginès, P.; Wong, F.; Bernardi, M.; Boyer, T.D.; Gerbes, A.; Moreau, R.; Jalan, R.; Sarin, S.K .; Piano, S., et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. Journal of hepatology 2015, 62, 968 – 974, doi:10.1016/j.jhep.2014.12.029.
30) Poynard, T.; Mathurin, P.; Lai, C.L.; Guyader, D.; Poupon, R.; Tainturier, M.H.; Myers, R.P .; Muntenau, M.; Ratziu, V.; Manns, M., et al. A comparison of fibrosis progression in chronic liver diseases. Journal of hepatology 2003, 38, 257-265 .
31) Sun, M.; Kisseleva, T. Reversibility of liver fibrosis. Clinics and research in hepatology and gastroenterology 2015, 39 Suppl 1, S60-63, doi:10.1016/j.clinre.2015.06.015
32) Friedman, S.L. Evolving challenges in hepatic fibrosis. Nature reviews. Gastroenterology & hepatology 2010, 7, 425-436, doi:10.1038/nrgastro.2010.97.; quiz 1071-1062, doi:10.1007/s00108-011-2853-0
33) Benyon, R.C.; Arthur, M.J.P. Extracellular Matrix Degradation and the Role of Hepatic Stellate Cells . Semin Liver Dis 2001, 21, 373-384, doi:10.1055/s-2001-17552 .
34) Horvat, T.; Landesmann, B.; Lostia, A.; Vinken, M.; Munn, S.; Whelan, M. Adverse outcome pathway development from protein alkylation to liver fibrosis. Archives of toxicology 2017, 91, 1523-1543 , doi:10.1007/s00204-016-1814-8 .

35) Bruha, R.; Dvorak, K.; Petrtyl, J. Alcoholic liver disease. World journal of hepatology 2012, 4, 81-90 , doi:10.4254/wjh.v4.i3.81 .
36) Askgaard, G.; Gronbaek, M.; Kjaer, M.S.; Tjonneland, A.; Tolstrup, J.S. Alcohol drinking pattern and risk of alcoholic liver cirrhosis: a prospective cohort study. Journal of hepatology 2015, 62, 1061-1067 , doi:10.1016/j.jhep.2014.12.005
37) Osna, N.A.; Donohue, T.M., Jr.; Kharbanda, K.K. Alcoholic Liver Disease: Pathogenesis and Current Management. Alcohol research : current reviews 2017, 38, 147-161 .
38) Hagström, H. Alcohol Consumption in Concomitant Liver Disease: How Much is Too Much? Current hepatology reports 2017, 16, 152-157, doi:10.1007/s11901-017-0343-0 .
39) Whitfield, J.B.; Masson, S.; Liangpunsakul, S.; Hyman, J.; Mueller, S.; Aithal, G.; Eyer, F.; Gleeson, D .; Thompson, A.; Stickel, F. Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis. Alcohol 2018, 66, 1-7 .
40) Scaglione, S.; Kliethermes, S.; Cao, G.; Shoham, D.; Durazo, R.; Luke, A.; Volk, M.L. The epidemiology of cirrhosis in the United States. Journal of clinical gastroenterology 2015, 49, 690-696.
41) El‐Serag, H.; Kramer, J.; Duan, Z.; Kanwal, F. Epidemiology and outcomes of hepatitis C infection in elderly US Veterans. Journal of viral hepatitis 2016, 23, 687-696 .
42) Thrift, A.P.; El-Serag, H.B.; Kanwal, F. Global epidemiology and burden of HCV infection and HCV – related disease. Nature reviews Gastroenterology & hepatology 2017, 14, 122 .
43) van der Meer, A.J.; Feld, J.J.; Hofer, H.; Almasio, P.L.; Calvaruso, V.; Fernández-Rodríguez, C.M .; Aleman, S.; Ganne-Carrié, N.; D’Ambrosio, R.; Pol, S. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. Journal of hepatology 2017, 66
44) Rüeger, S.; Bochud, P.; Dufour, J.-F.; Müllhaupt, B.; Semela, D.; Heim, M.; Moradpour, D.; Cerny, A .; Malinverni, R.; Booth, D. Impact of common risk factors of fibrosis progression in chronic hepatitis C . Gut 2015, 64, 1605-1615.
45) Millman, A.J.; Nelson, N.P.; Vellozzi, C. Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct-Acting Antiviral Era. Current epidemiology reports 2017, 4, 174-185
46) EASL Recommendations on Treatment of Hepatitis C 2018. Journal of hepatology 2018, 69, 461-511 , doi:10.1016/j.jhep.2018.03.026.
47) Terrault, N.A.; Bzowej, N.H.; Chang, K.M.; Hwang, J.P.; Jonas, M.M.; Murad, M.H. A ASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016, 63, 261-283.
48) Schweitzer, A.; Horn, J.; Mikolajczyk, R.T.; Krause, G.; Ott, J.J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 . The Lancet 2015, 386, 1546-1555.
49) Lavanchy, D.; Kane, M. Global epidemiology of hepatitis B virus infection. In Hepatitis B virus in human diseases, Springer: 2016; pp. 187-203 .
50) Bogler, Y.; Wong, R.J.; Gish, R.G. Epidemiology and Natural History of Chronic Hepatitis B Virus Infection. In Hepatitis B Virus and Liver Disease, Springer: 2018; pp. 63-89
51) Nannini, P.; Sokal, E.M. Hepatitis B: changing epidemiology and interventions. Archives of disease in childhood 2017, 102, 676-680.
52) Nelson, N.P.; Easterbrook, P.J.; McMahon, B.J. Epidemiology of hepatitis B virus infection and impact of vaccination on disease. Clinics in liver disease 2016, 20, 607-628.
53) Zhang, X.J.; She, Z.G.; Li, H. Time to step‐up the fight against NAFLD. Hepatology 2018, 67, 2068-2071
54) Buzzetti, E.; Pinzani, M.; Tsochatzis, E.A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016, 65, 1038-1048.
55) Dowman, J.K.; Farrell, G.C.; Newsome, P. NAFLD: A worldwide problem. Clinical Dilemmas in Non – Alcoholic Fatty Liver Disease 2016, 20, 8 .
56) McPherson, S.; Hardy, T.; Henderson, E.; Burt, A.D.; Day, C.P.; Anstee, Q.M. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. Journal of hepatology 2015, 62, 1148-1155
57) Rinella, M.E.; Sanyal, A.J. Management of NAFLD: a stage-based approach. Nature reviews Gastroenterology & hepatology 2016, 13, 196.
58) Liberal, R.; Krawitt, E.L.; Vierling, J.M.; Manns, M.P.; Mieli-Vergani, G.; Vergani, D. Cutting edge issues in autoimmune hepatitis. Journal of autoimmunity 2016, 75, 6-19.
59) Czaja, A.J. Global disparities and their implications in the occurrence and outcome of autoimmune hepatitis. Digestive diseases and sciences 2017, 62, 2277-2292.
60) Liberal, R.; de Boer, Y.S.; Andrade, R.J.; Bouma, G.; Dalekos, G.N.; Floreani, A.; Gleeson, D .; Hirschfield, G.M.; Invernizzi, P.; Lenzi, M. Expert clinical management of autoimmune hepatitis in the real world. Alimentary pharmacology & therapeutics 2017, 45, 723-732.
61) Rawla, P.; Samant, H. Primary Sclerosing Cholangitis. In StatPearls, StatPearls Publishing. StatPearls Publishing LLC.: Treasure Island (FL), 2018.
62) Lazaridis, K.N.; LaRusso, N.F. Primary sclerosing cholangitis. New England Journal of Medicine 2016 , 375, 1161-1170.
63) Lindor, K.D.; Kowdley, K.V.; Harrison, M.E. ACG clinical guideline: primary sclerosing cholangitis . The American journal of gastroenterology 2015, 110, 646.
64) Carey, E.J.; Ali, A.H.; Lindor, K.D. Primary biliary cirrhosis. The Lancet 2015, 386, 1565-1575
65) Liver, E.A.f.t.S.o.t. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. Journal of hepatology 2017, 67, 145-172.
66) Hirschfield, G.M.; Dyson, J.K.; Alexander, G.J.; Chapman, M.H.; Collier, J.; Hübscher, S.; Patanwala, I .; Pereira, S.P.; Thain, C.; Thorburn, D. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut 2018, 67, 1568-1594 .
67) Thuluvath, P.J.; Kantsevoy, S.; Thuluvath, A.J.; Savva, Y. Is cryptogenic cirrhosis different from NASH cirrhosis? Journal of hepatology 2018, 68, 519-525.
68) Henry, Z.; Argo, C.K.; Caldwell, S.H. Cryptogenic Cirrhosis. In Clinical Epidemiology of Chronic Liver Diseases, Springer: 2019; pp. 331-349.
69) Schuppan, D.; Afdhal, N.H. Liver cirrhosis. Lancet 2008, 371, 838-851, doi:10.1016/s0140 – 6736(08) 03836-9.
70) Porter, J.L.; Rawla, P. Hemochromatosis. In StatPearls, StatPearls Publishing. StatPearls Publishing LLC.: Treasure Island (FL), 2018 .
71) Fukui, H.; Saito, H.; Ueno, Y.; Uto, H.; Obara, K.; Sakaida, I.; Shibuya, A.; Seike, M.; Nagoshi, S .; Segawa, M. Evidence-based clinical practice guidelines for liver cirrhosis 2015. Journal of gastroenterology 2016, 51, 629-650.
72) Ahmed, Z.; Ahmed, U.; Walayat, S.; Ren, J.; Martin, D.K.; Moole, H.; Koppe, S.; Yong, S.; Dhillon, S . Liver function tests in identifying patients with liver disease. Clinical and experimental gastroenterology 2028, 11, 301-307, doi:10.2147/CEG.S160537.

73) Giannini, E.G.; Testa, R.; Savarino, V. Liver enzyme alteration: a guide for clinicians. CMAJ : Canadian Medical Association journal = journal de l’Association medicale canadienne 2005, 172, 367-379 , doi:10.1503/cmaj.1040752.
74) McLernon, D.J.; Donnan, P.T.; Sullivan, F.M.; Roderick, P.; Rosenberg, W.M.; Ryder, S.D.; Dillon, J.F . Prediction of liver disease in patients whose liver function tests have been checked in primary care : model development and validation using population-based observational cohorts. BMJ open 2014, 4 , e004837-e004837, doi:10.1136/bmjopen-2014-004837.
75) Walayat, S.; Martin, D.; Patel, J.; Ahmed, U.; N Asghar, M.; Pai, A.U.; Dhillon, S. Role of albumin in cirrhosis: from a hospitalist’s perspective. Journal of community hospital internal medicine perspectives 2027 , 7, 8-14, doi:10.1080/20009666.2017.1302704.
76) Blasi, A. Coagulopathy in liver disease: Lack of an assessment tool. World journal of gastroenterology 2015 , 21, 10062-10071, doi:10.3748/wjg.v21.i35.10062.
77) Marks, P.W. Hematologic manifestations of liver disease. Seminars in hematology 2013, 50, 216-221 , doi:10.1053/j.seminhematol.2013.06.003.
78) Qamar, A.A.; Grace, N.D. Abnormal hematological indices in cirrhosis. Canadian journal of gastroenterology = Journal canadien de gastroenterologie 2009, 23, 441-445 .
79) Newsome, P.N.; Cramb, R.; Davison, S.M.; Dillon, J.F.; Foulerton, M.; Godfrey, E.M.; Hall, R .; Harrower, U.; Hudson, M.; Langford, A., et al. Guidelines on the management of abnormal liver blood tests. Gut 2018, 67, 6, doi:10.1136/gutjnl-2017-314924
80) Kelly, E.M.M.; Feldstein, V.A.; Parks, M.; Hudock, R.; Etheridge, D.; Peters, M.G. An Assessment of the Clinical Accuracy of Ultrasound in Diagnosing Cirrhosis in the Absence of Portal Hypertension . Gastroenterology & hepatology 2018, 14, 367-373
81) Procopet, B.; Berzigotti, A. Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy. Gastroenterology report 2017, 5, 79-89, doi:10.1093/gastro/gox012
82) Gherlan, G.S. Liver ultrasound elastography: More than staging the disease. World journal of hepatology 2015, 7, 1595-1600, doi:10.4254/wjh.v7.i12.1595.
83) Srinivasa Babu, A.; Wells, M.L.; Teytelboym, O.M.; Mackey, J.E.; Miller, F.H.; Yeh, B.M.; Ehman, R.L .; Venkatesh, S.K. Elastography in Chronic Liver Disease: Modalities, Techniques, Limitations, and Future Directions. Radiographics : a review publication of the Radiological Society of North America, Inc 2016 , 36, 1987-2006, doi:10.1148/rg.2016160042.
84) Song, J.E.; Lee, D.W.; Kim, E.Y. Endoscopic Ultrasound Real-Time Elastography in Liver Disease Clinical endoscopy 2018, 51, 118-119, doi:10.5946/ce.2018.049
85) Lertpipopmetha, K.; Tubtawee, T.; Piratvisuth, T.; Chamroonkul, N. Comparison between Computer Tomography and Magnetic Resonance Imaging in the Diagnosis of Small Hepatocellular Carcinoma . Asian Pacific journal of cancer prevention : APJCP 17, 4805-4811, doi:10.22034/APJCP.2016.17.11.4805
86) de Ledinghen, V.; Laharie, D.; Lecesne, R.; Le Bail, B.; Winnock, M.; Bernard, P.H.; Saric, J.; Couzigou , P.; Balabaud, C.; Bioulac-Sage, P., et al. Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients European journal of gastroenterology & hepatology 2002, 14, 159-165
87) Thampanitchawong, P.; Piratvisuth, T. Liver biopsy:complications and risk factors. World journal of gastroenterology 1999, 5, 301-304, doi:10.3748/wjg.v5.i4.301

88) Germani, G.; Hytiroglou, P.; Fotiadu, A.; Burroughs, A.K.; Dhillon, A.P. Assessment of fibrosis and cirrhosis in liver biopsies: an update. Semin Liver Dis 2011, 31, 82-90, doi:10.1055/s-0031-1272836
89) Tannapfel, A.; Dienes, H.-P.; Lohse, A.W. The indications for liver biopsy. Deutsches Arzteblatt international 2012, 109, 477-483, doi:10.3238/arztebl.2012.